Recently, the CEO of KT&G, Baek Bok-in, expressed his company's intention to become a "top global enterprise" and reach a sales revenue of 100 trillion KRW by 2027 during a vision declaration ceremony.
Bai Furui plans to elevate their tobacco and healthcare businesses to a global level within the next four years. They will prioritize their two primary pillars of the tobacco industry, which includes NGP (Next Generation Products), cigarettes, and healthcare products as their core businesses in order to maximize their competitiveness in foreign markets.
Baek Bok-in also revealed specific targets for each project. Cigarette sales are expected to reach 38 trillion won, NGP 28 trillion won, and health products 21 trillion won, totaling 80 trillion won, an increase of over 60% compared to last year's estimated 49 trillion won. The proportion of global business to total sales is expected to increase from last year's 33% to over 50% by 2027 (excluding real estate).
Therefore, Bai Furen will carry out a large-scale facility investment of approximately 4 trillion Korean won.
Picture: President of KT&G, Baek Bok-in, Source: The Shin-Il Daily News
Reference:
KT&G's Baek Bok-in takes on the world market to enhance cigarette competitiveness in the latest installment of "A New Start for Distribution".
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
